{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:42:00Z","timestamp":1792618920443,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82441036"],"award-info":[{"award-number":["82441036"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Colorectal cancer (CRC) remains largely refractory to immune-checkpoint blockade, with\n                    <jats:italic>adenomatous polyposis coli<\/jats:italic>\n                    (\n                    <jats:italic>APC<\/jats:italic>\n                    ) mutations present in 80%\u201390% of cases. Loss of APC was previously thought to promote tumor progression mainly through deregulated Wnt\/\u03b2-catenin signaling. Here, we report that APC loss leads to inhibition of CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell infiltration and CRC immune evasion through the dephosphorylation of signal transducers and activators of transcription 1 (STAT1) by protein tyrosine phosphatase non-receptor type 13 (PTPN13), independently of \u03b2-catenin. Peptides containing the last 11 C-terminal amino acid (aa) residues of APC (APC11) bind directly to PTPN13 to block PTPN13\u2013STAT1 interactions and facilitate STAT1 phosphorylation, interferon regulatory factor-1 (IRF1) expression, major histocompatibility complex (MHC) class I antigen presentation, and T cell intratumoral infiltration, all of which eventually inhibit tumor progression and enhance the effects of programmed cell death 1 (PD1) blockade. Thus, we have identified a previously unknown APC\/PTPN13\/STAT1-dependent tumor immune-suppressive mechanism. The potent tumor-suppressing effect of combining anti-PD1 antibodies with APC11 peptides provides a compelling target and rationale for future development of anti-tumor drugs for patients with CRC.\n                  <\/jats:p>","DOI":"10.1038\/s41422-025-01206-4","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T01:02:00Z","timestamp":1767574920000},"page":"72-93","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Targeting PTPN13 with 11-amino-acid peptides of C-terminal APC prevents immune evasion of colorectal cancer"],"prefix":"10.1038","volume":"36","author":[{"given":"Wen-Hui","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqian","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue-Hong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo-Luo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-Fang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Yue","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangnan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao-Kun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4536-6191","authenticated-orcid":false,"given":"Yi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9631-4781","authenticated-orcid":false,"given":"Xiaochun","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1817-7229","authenticated-orcid":false,"given":"Dalei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2773-7048","authenticated-orcid":false,"given":"Guoxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0021-9454","authenticated-orcid":false,"given":"Wei-Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"1206_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"1206_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"1206_CR3","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350\u20131355 (2018).","journal-title":"Science"},{"key":"1206_CR4","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450\u2013461 (2015).","journal-title":"Cancer Cell"},{"key":"1206_CR5","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","volume":"372","author":"DT Le","year":"2015","unstructured":"Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509\u20132520 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1206_CR6","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","volume":"36","author":"MJ Overman","year":"2018","unstructured":"Overman, M. J. et al. Durable clinical benefit with Nivolumab plus Ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773\u2013779 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1206_CR7","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andre","year":"2020","unstructured":"Andre, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1206_CR8","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1038\/nm.3967","volume":"21","author":"J Guinney","year":"2015","unstructured":"Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350\u20131356 (2015).","journal-title":"Nat. Med."},{"key":"1206_CR9","first-page":"148","volume":"145","author":"H Kim","year":"1994","unstructured":"Kim, H., Jen, J., Vogelstein, B. & Hamilton, S. R. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am. J. Pathol. 145, 148\u2013156 (1994).","journal-title":"Am. J. Pathol."},{"key":"1206_CR10","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1056\/NEJM200001133420201","volume":"342","author":"R Gryfe","year":"2000","unstructured":"Gryfe, R. et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med. 342, 69\u201377 (2000).","journal-title":"N. Engl. J. Med."},{"key":"1206_CR11","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/sj.bjc.6604867","volume":"100","author":"M Koopman","year":"2009","unstructured":"Koopman, M. et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br. J. Cancer 100, 266\u2013273 (2009).","journal-title":"Br. J. Cancer"},{"key":"1206_CR12","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med."},{"key":"1206_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1200\/JCO.22.02270","volume":"41","author":"JR Brahmer","year":"2023","unstructured":"Brahmer, J. R. et al. Phase I study of single-agent anti-programmed Death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 41, 715\u2013723 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1206_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0454-7","volume":"15","author":"AR Brannon","year":"2014","unstructured":"Brannon, A. R. et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. 15, 454 (2014).","journal-title":"Genome Biol."},{"key":"1206_CR15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nature11252","volume":"487","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330\u2013337 (2012).","journal-title":"Nature"},{"key":"1206_CR16","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cell.2019.03.030","volume":"177","author":"S Vasaikar","year":"2019","unstructured":"Vasaikar, S. et al. Proteogenomic analysis of human colon cancer reveals new therapeutic opportunities. Cell 177, 1035\u20131049.e19 (2019).","journal-title":"Cell"},{"key":"1206_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/0092-8674(81)90021-0","volume":"66","author":"J Groden","year":"1991","unstructured":"Groden, J. et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66, 589\u2013600 (1991).","journal-title":"Cell"},{"key":"1206_CR18","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1126\/science.1848370","volume":"251","author":"KW Kinzler","year":"1991","unstructured":"Kinzler, K. W. et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251, 1366\u20131370 (1991).","journal-title":"Science"},{"key":"1206_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1126\/science.1651563","volume":"253","author":"I Nishisho","year":"1991","unstructured":"Nishisho, I. et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253, 665\u2013669 (1991).","journal-title":"Science"},{"key":"1206_CR20","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41586-024-08053-0","volume":"634","author":"D Iannish","year":"2024","unstructured":"Iannish, D. et al. Polyclonality overcomes fitness barriers in Apc-driven tumorigenesis. Nature 634, 1196\u20131203 (2024).","journal-title":"Nature"},{"key":"1206_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1126\/scitranslmed.aaf8127","volume":"8","author":"L Zhang","year":"2016","unstructured":"Zhang, L. et al. Selective targeting of mutant adenomatous polyposis coli (APC) in colorectal cancer. Sci. Transl. Med. 8, 361 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1206_CR22","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41589-025-01870-y","volume":"21","author":"A Sharma","year":"2025","unstructured":"Sharma, A. et al. Cholesterol-targeting Wnt-\u03b2-catenin signaling inhibitors for colorectal cancer. Nat. Chem. Biol. 21, 1376\u20131386 (2025).","journal-title":"Nat. Chem. Biol."},{"key":"1206_CR23","doi-asserted-by":"crossref","unstructured":"McHeik, S., Aptecar, L., Coopman, P., D\u2019Hondt, V. & Freiss, G. Dual role of the PTPN13 tyrosine phosphatase in cancer. Biomolecules 10, 1659 (2020).","DOI":"10.3390\/biom10121659"},{"key":"1206_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nature12416","volume":"501","author":"WJ Zhou","year":"2013","unstructured":"Zhou, W. J., Geng, Z. H., Spence, J. R. & Geng, J. G. Induction of intestinal stem cells by R-spondin 1 and Slit2 augments chemoradioprotection. Nature 501, 107\u2013111 (2013).","journal-title":"Nature"},{"key":"1206_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet"},{"key":"1206_CR26","first-page":"1361","volume":"8","author":"M Buchert","year":"2015","unstructured":"Buchert, M. et al. A hypermorphic epithelial beta-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations. Dis. Model. Mech. 8, 1361\u20131373 (2015).","journal-title":"Dis. Model. Mech."},{"key":"1206_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrc1837","volume":"6","author":"A Ostman","year":"2006","unstructured":"Ostman, A., Hellberg, C. & Bohmer, F. D. Protein-tyrosine phosphatases and cancer. Nat. Rev. Cancer 6, 307\u2013320 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"1206_CR28","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nature23270","volume":"547","author":"RT Manguso","year":"2017","unstructured":"Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413\u2013418 (2017).","journal-title":"Nature"},{"key":"1206_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.immuni.2007.01.010","volume":"26","author":"M Nakahira","year":"2007","unstructured":"Nakahira, M., Tanaka, T., Robson, B. E., Mizgerd, J. P. & Grusby, M. J. Regulation of signal transducer and activator of transcription signaling by the tyrosine phosphatase PTP-BL. Immunity 26, 163\u2013176 (2007).","journal-title":"Immunity"},{"key":"1206_CR30","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1038\/sj.onc.1203725","volume":"19","author":"KS Erdmann","year":"2000","unstructured":"Erdmann, K. S. et al. The Adenomatous Polyposis Coli-protein (APC) interacts with the protein tyrosine phosphatase PTP-BL via an alternatively spliced PDZ domain. Oncogene 19, 3894\u20133901 (2000).","journal-title":"Oncogene"},{"key":"1206_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nm996","volume":"10","author":"JS Wadia","year":"2004","unstructured":"Wadia, J. S., Stan, R. V. & Dowdy, S. F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10, 310\u2013315 (2004).","journal-title":"Nat. Med."},{"key":"1206_CR32","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1021\/bi101131f","volume":"49","author":"J Zhang","year":"2010","unstructured":"Zhang, J. et al. Crystallographic and nuclear magnetic resonance evaluation of the impact of peptide binding to the second PDZ domain of protein tyrosine phosphatase 1E. Biochemistry 49, 9280\u20139291 (2010).","journal-title":"Biochemistry"},{"key":"1206_CR33","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","volume":"35","author":"E Beddowes","year":"2017","unstructured":"Beddowes, E. et al. Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1-deficient thoracic cancers. J. Clin. Oncol. 35, 1778\u20131785 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1206_CR34","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.1183057","volume":"328","author":"KN Sugahara","year":"2010","unstructured":"Sugahara, K. N. et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328, 1031\u20131035 (2010).","journal-title":"Science"},{"key":"1206_CR35","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1126\/science.280.5363.596","volume":"280","author":"J Behrens","year":"1998","unstructured":"Behrens, J. et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science 280, 596\u2013599 (1998).","journal-title":"Science"},{"key":"1206_CR36","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1242\/jcs.100479","volume":"126","author":"S Nelson","year":"2013","unstructured":"Nelson, S. & Nathke, I. S. Interactions and functions of the adenomatous polyposis coli (APC) protein at a glance. J. Cell Sci. 126, 873\u2013877 (2013).","journal-title":"J. Cell Sci."},{"key":"1206_CR37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.celrep.2017.09.020","volume":"21","author":"S Aguera-Gonzalez","year":"2017","unstructured":"Aguera-Gonzalez, S. et al. Adenomatous polyposis coli defines treg differentiation and anti-inflammatory function through microtubule-mediated NFAT localization. Cell Rep. 21, 181\u2013194 (2017).","journal-title":"Cell Rep."},{"key":"1206_CR38","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1111\/j.1349-7006.2009.01287.x","volume":"100","author":"K Yoshimi","year":"2009","unstructured":"Yoshimi, K. et al. Enhanced colitis-associated colon carcinogenesis in a novel Apc mutant rat. Cancer Sci. 100, 2022\u20132027 (2009).","journal-title":"Cancer Sci."},{"key":"1206_CR39","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/hmg\/1.4.229","volume":"1","author":"Y Miyoshi","year":"1992","unstructured":"Miyoshi, Y. et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum. Mol. Genet. 1, 229\u2013233 (1992).","journal-title":"Hum. Mol. Genet"},{"key":"1206_CR40","first-page":"113","volume":"3","author":"WM Clements","year":"2003","unstructured":"Clements, W. M., Lowy, A. M. & Groden, J. Adenomatous polyposis coli\/beta-catenin interaction and downstream targets: altered gene expression in gastrointestinal tumors. Clin. Colorectal Cancer 3, 113\u2013120 (2003).","journal-title":"Clin. Colorectal Cancer"},{"key":"1206_CR41","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(17)30336-4","volume":"18","author":"J Tseng","year":"2017","unstructured":"Tseng, J. et al. Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. Lancet Oncol. 18, 711\u2013712 (2017).","journal-title":"Lancet Oncol."},{"key":"1206_CR42","doi-asserted-by":"crossref","unstructured":"Du, L. et al. beta-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J. Exp. Med. 217, e20191115 (2020).","DOI":"10.1084\/jem.20191115"},{"key":"1206_CR43","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","volume":"37","author":"H Liu","year":"2020","unstructured":"Liu, H. et al. ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 axis. Cancer Cell 37, 324\u2013339.e8 (2020).","journal-title":"Cancer Cell"},{"key":"1206_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.2174\/187152011794941262","volume":"11","author":"G Freiss","year":"2011","unstructured":"Freiss, G. & Chalbos, D. PTPN13\/PTPL1: an important regulator of tumor aggressiveness. Anticancer Agents Med. Chem. 11, 78\u201388 (2011).","journal-title":"Anticancer Agents Med. Chem."},{"key":"1206_CR45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrc2980","volume":"11","author":"SG Julien","year":"2011","unstructured":"Julien, S. G., Dube, N., Hardy, S. & Tremblay, M. L. Inside the human cancer tyrosine phosphatome. Nat. Rev. Cancer 11, 35\u201349 (2011).","journal-title":"Nat. Rev. Cancer"},{"key":"1206_CR46","doi-asserted-by":"publisher","first-page":"4789","DOI":"10.1046\/j.1432-1033.2003.03895.x","volume":"270","author":"KS Erdmann","year":"2003","unstructured":"Erdmann, K. S. The protein tyrosine phosphatase PTP-Basophil\/Basophil-like. Interacting proteins and molecular functions. Eur. J. Biochem. 270, 4789\u20134798 (2003).","journal-title":"Eur. J. Biochem."},{"key":"1206_CR47","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/onc.2013.80","volume":"33","author":"J Stebbing","year":"2014","unstructured":"Stebbing, J. et al. The regulatory roles of phosphatases in cancer. Oncogene 33, 939\u2013953 (2014).","journal-title":"Oncogene"},{"key":"1206_CR48","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10555-008-9114-2","volume":"27","author":"OD Abaan","year":"2008","unstructured":"Abaan, O. D. & Toretsky, J. A. PTPL1: a large phosphatase with a split personality. Cancer Metastasis Rev. 27, 205\u2013214 (2008).","journal-title":"Cancer Metastasis Rev."},{"key":"1206_CR49","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7150\/thno.38537","volume":"10","author":"M Hamyeh","year":"2020","unstructured":"Hamyeh, M. et al. PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness. Theranostics 10, 1016\u20131032 (2020).","journal-title":"Theranostics"},{"key":"1206_CR50","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41388-020-01498-3","volume":"40","author":"Y Yan","year":"2021","unstructured":"Yan, Y. et al. Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression. Oncogene 40, 28\u201345 (2021).","journal-title":"Oncogene"},{"key":"1206_CR51","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/bioinformatics\/btt755","volume":"30","author":"B Niu","year":"2014","unstructured":"Niu, B. et al. MSIsensor: microsatellite instability detection using paired tumor-normal sequence data. Bioinformatics 30, 1015\u20131016 (2014).","journal-title":"Bioinformatics"},{"key":"1206_CR52","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/nbt.3026","volume":"32","author":"JG Doench","year":"2014","unstructured":"Doench, J. G. et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat. Biotechnol. 32, 1262\u20131267 (2014).","journal-title":"Nat. Biotechnol."},{"key":"1206_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"1206_CR54","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1093\/nar\/gkv1507","volume":"44","author":"A Colaprico","year":"2016","unstructured":"Colaprico, A. et al. TCGAbiolinks: an R\/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 44, e71 (2016).","journal-title":"Nucleic Acids Res"},{"key":"1206_CR55","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1016\/j.cell.2019.07.021","volume":"178","author":"M Xu","year":"2019","unstructured":"Xu, M. et al. LECT2, a ligand for tie1, plays a crucial role in liver fibrogenesis. Cell 178, 1478\u20131492.e20 (2019).","journal-title":"Cell"},{"key":"1206_CR56","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"1206_CR57","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1107\/S0907444906019949","volume":"62","author":"W Minor","year":"2006","unstructured":"Minor, W., Cymborowski, M., Otwinowski, Z. & Chruszcz, M. HKL-3000: the integration of data reduction and structure solution-from diffraction images to an initial model in min. Acta Crystallogr. D Biol. Crystallogr. 62, 859\u2013866 (2006).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"1206_CR58","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"1206_CR59","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"1206_CR60","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D Biol. Crystallogr."}],"container-title":["Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41422-025-01206-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41422-025-01206-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41422-025-01206-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T03:02:57Z","timestamp":1768964577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41422-025-01206-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1206"],"URL":"https:\/\/doi.org\/10.1038\/s41422-025-01206-4","relation":{},"ISSN":["1748-7838"],"issn-type":[{"value":"1748-7838","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}